C

Cybin Inc
F:R7E1

Watchlist Manager
Cybin Inc
F:R7E1
Watchlist
Price: 13 EUR 17.12% Market Closed
Market Cap: 9.9B EUR

Relative Value

There is not enough data to reliably calculate the relative value of R7E1.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

R7E1 Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.7
vs History
vs Industry
Median 3Y
-176.4
Median 5Y
-295.2
Industry
21.5
Forward
-20.1
vs History
vs Industry
Median 3Y
-199.9
Median 5Y
-307.5
Industry
16.7
vs History
vs Industry
Median 3Y
-197.5
Median 5Y
-288.1
Industry
23
vs History
68
vs Industry
Median 3Y
55.9
Median 5Y
297.1
Industry
2.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.6
vs History
vs Industry
Median 3Y
-173
Median 5Y
-285.6
Industry
13.2
Forward
-166
vs History
vs Industry
Median 3Y
-172.1
Median 5Y
-284.1
Industry
16.6
Forward
-167.4
vs History
vs Industry
Median 3Y
-196.9
Median 5Y
-307.3
Industry
15.8
vs History
vs Industry
Median 3Y
-194.9
Median 5Y
-287.9
Industry
19
vs History
73
vs Industry
Median 3Y
158.4
Median 5Y
475.1
Industry
2

Multiples Across Competitors

R7E1 Competitors Multiples
Cybin Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Cybin Inc
F:R7E1
6.3B EUR 0 -70.5 -58.4 -58.3
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.4 37.1 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
499.6B USD 5.4 19.9 16.3 21.1
CH
Roche Holding AG
SIX:ROG
262.5B CHF 4.3 27.8 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
212B GBP 4.9 30.5 108.5 158.8
CH
Novartis AG
SIX:NOVN
211.3B CHF 4.8 18.6 11.8 15.2
US
Merck & Co Inc
NYSE:MRK
265.6B USD 4.1 14 9.9 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.7 14.2 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
212.8B USD 91.8 -72.8 337 845
US
Pfizer Inc
NYSE:PFE
142.7B USD 2.3 14.5 7.4 10.1
P/S Multiple
Revenue Growth P/S to Growth
CA
C
Cybin Inc
F:R7E1
Average P/S: 71.8
Not Available
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
17.2
26%
0.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
9%
64.3
US
Johnson & Johnson
NYSE:JNJ
5.4
6%
0.9
CH
Roche Holding AG
SIX:ROG
4.3
3%
1.4
UK
AstraZeneca PLC
LSE:AZN
4.9
8%
0.6
CH
Novartis AG
SIX:NOVN
4.8
5%
1
US
Merck & Co Inc
NYSE:MRK
4.1
4%
1
DK
Novo Nordisk A/S
CSE:NOVO B
4.7
5%
0.9
IE
E
Endo International PLC
LSE:0Y5F
91.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
2.3
-2%
N/A
P/E Multiple
Earnings Growth PEG
CA
C
Cybin Inc
F:R7E1
Average P/E: 24.4
Negative Multiple: -70.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.4
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.5
37%
0.8
CH
Novartis AG
SIX:NOVN
18.6
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
3%
4.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -72.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
C
Cybin Inc
F:R7E1
Average EV/EBITDA: 439.6
Negative Multiple: -58.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.1
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.5
10%
10.9
CH
Novartis AG
SIX:NOVN
11.8
6%
2
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
1%
9.9
IE
E
Endo International PLC
LSE:0Y5F
337
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
C
Cybin Inc
F:R7E1
Average EV/EBIT: 1 883
Negative Multiple: -58.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.8
23%
6.9
CH
Novartis AG
SIX:NOVN
15.2
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
845
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
7%
1.4